In this work, we introduce 6-['sFlfluoro-L-m tyrosine (6-FMT) and compare its in-vivo kinetic and bio chemical behaviors in monkeys and rodents with those of 4-FMT and 6-['sFlfluoro-L-3,4-dihydroxyphenylalanine (DOPA) (FDOPA). These radiofluorinated m-tyrosine presynaptic dopaminergic probes, resistant to peripheral 3-0-methylation, offer a nonpharmacologicai alternative to the use of catechol-O-methyltransferase inhibitors. Like FDOPA, 4-FMT and 6-FMT are analogs that essen tially follow the L-DOPA pathway of central metabolism. After i.v. administration in nonhuman primates and ro dents, these new radiofluorinated m-tyrosine analogs ac cumulate selectively in striatal structures and allow for Positron emission tomographic (PET) scanning with 6-[18F]fluoro-L-3 ,4-dihydroxyphenylalanine (FDOPA) provides a means to visualize the dopa minergic system in central brain structures (Garnett
the detection of additional innervation sites (e.g., brain stem) rich in aromatic amino acid decarboxylase. Bio chemical analyses in rodents and monkeys revealed the specificity of their central and peripheral metabolism. Molecular and enzymatic mechanisms involved in their retention in central brain structures are consistent with involvement of dopaminergic neurons. The high signal to-noise ratios observed make these radiofluorinated m-tyrosine analogs outstanding candidates for probing the integrity of central dopaminergic mechanisms in hu mans. Key Words: 6-[18Flfluoro-L-m-tryosine-6-FMT-4--FMT-L-DOPA-Dopaminergic probes. et aI., 1983a; Caine et aI., 1985; Nahmias et aI., 1985; Chiueh et aI., 1986; Firnau et aI., 1986; Leen ders et aI., 1986a; Martin et aI., 1986; Guttman et aI., 1989) . Investigations in rodents (Cumming et aI., 1987; Melega et aI., 1990a,b) , nonhuman pri mates, (Garnett et aI., 1983b; Firnau et aI., 1987; Doudet et aI., 1989; Melega et aI., 1991a,b; Hoff man et aI., 1992) , and humans (Nahmias et aI., 1985; Hoffman et aI., 1992; Snow et aI., 1993) have un questionably demonstrated that accumulation of 18F activity in the basal ganglia is related to the integrity of dopaminergic neurons since that activity could be attributed to the aromatic amino acid decarbox ylase (AAAD, EC 4.1.1.28) mediated formation of 6-[18F]fluorodopamine (FDA) and its metabolites.
Moreover, in double-labeling experiments in rats, it had been shown that the cerebral metabolism of FDOPA and that of eH]-L-DOPA were correlated (Melega et aI., 1990b) . These results demonstrated that FDOPA was centrally decarboxylated by AAAD to FDA, which was mainly stored in a slow turnover rate functional pool. Very strong correla tions between FDOPA kinetics and severe nigro striatal degeneration were also demonstrated in both monkeys (Pate et aI., 1993) and humans (Snow et aI., 1993) . In I-methyl-4-phenyl-l ,2,3 ,6-tetra hydropyridine (MPTP)-treated hemiparkinsonian monkeys, FDOPA kinetics correlated with bio chemical data indicating that striatal concentrations of endogenous dopamine, 3,4-dihydroxyphenylace tic acid (DOPAC) and homo vanillic acid (HV A) were significantly reduced on the side of the nigro striatal lesion (Melega et aI., 1991b) .
Nevertheless, the peripheral metabolism of FDOPA can complicate interpretation of the in vivo data. Tracer kinetic modeling approaches to quan titate FDOPA transport, decarboxylation rates, and metabolite clearance should take into account the transformation of FDOPA into 3-0-methyl-6e S F]fluoro-L-DOPA (3-0MFD) in peripheral tis sues, as well as its brain transport and tissue distribution (Huang et aI., 1991; Gjedde et aI., 1991) . Catechol-O-methyltransferase (COMT, EC 2.1.1.6), the enzyme responsible for this transfor mation, can be inhibited in vivo (Guttman et aI., 1993) , reducing the formation of 3-0MFD and its effects on the kinetic data. In this work, we report a substantially different approach to address this problem: the development of fluorinated amino acid analogs that are substrates of AAAD, but inert to wards COMT. Herein, we present a comparative biochemical and kinetic evaluation of two such ra diofluorinated analogs, 6-e s F]fluoro-L-m-tyrosine (6-FMT) and 4-FMT (Melega et aI., 1989) , with FDOPA. These new analogs also provide further insight into peripheral and neuronal dopamine bio chemistry, allowing for a more accurate represen tation and understanding of the kinetic data obtain in vivo with FDOPA (Huang et aI., 1991; Gjedde et aI., 1991) .
MATERIALS AND METHODS

Chemicals
Monobasic sodium phosphate, l-octanesulfonic acid (OSA) sodium salt and arylsulfatase (Type VI, prepared from Aerobacter aerogenes) were purchased from Sigma Chemicals (St. Louis, MO, U.S.A.); perchloric acid (70% aqueous solution), and HPLC-grade methanol were pur chased from Fisher Scientific (Los Angeles, CA, U.S.A.); and sodium metabisulfite and ethylene diamine tetraacetic acid (EDT A) disodium salt from EM Science (Gibbstown, NJ, U.S.A.). L-a-hydrazino-a-methyl-r3-(3,4-dihydroxyphenyl)propionic acid (carbidopa) was a gift from Merck, Sharp, and Dohme.
Synthesis methods
FDOPA, 4-FMT, and 6-FMT (specific activity: 1-5 CiJ mmo\) were prepared by using the radiofluorodestanny lation procedures previously described (Namavari et aI., 1992 (Namavari et aI., , 1993 Satyamurthy et aI., 1994) . The enantiomeric purities of the L-form of these radiolabeled amino acids were >99%.
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Tomographic imaging in primates
Tomographic studies were performed in adult primates [Cercopithecus aethiops (vervet), 6-8 kg, n = 9]. On the evening prior to the PET study, the monkey was main tained on a low-protein diet and kept fasted after mid night. This requirement controls competing large neutral amino acids, the presence of which would reduce the brain transport of the radiofluorinated L-DOPA analogs at the large amino acid carrier transport site at the blood brain barrier (BBB) (Leenders et aI., 1986b) . The morning of the study, all necessary equipment was sterilized and the animal examined and its condition noted. If the animal was found to be in a normal state, initial anesthetization was carried out with 4-6 mg/kg ketamine i.m. The animal was also given 5.4 fJ.,g/kg atropine sulfate and was then transported to the PET Laboratory. A peripheral i. v. line was placed and the animal given 15 mg/kg of pentobar bital (nembutal) or maintained anesthetic ally by halo thane inhalant techniques (1-2%). Animals were never rescanned within a period of �2 weeks. Tomographic data were obtained with a high resolution animal PET scanner (Cn, Knoxville, TN, U.S.A.) that collects 15 planes of data simultaneously in an axial span of 5 cm (Cutler et aI., 1992) . Interleaved scanning (axially) in creased the number of planes to 30, improving axial sam pling and leading to a uniform resolution of �5 mm. The animal was then placed supine in the tomograph bed with the head in the gantry on a custom cradle designed to support and prevent head movement. One hour prior to scanning, 5 mg/kg of carbidopa i.m. was administered to minimize the spectrum of labeled metabolites formed sys temically and to increase bioavailability of the radiola beled amino acid probe (Melega et aI., 1990a) . The animal was then positioned in the tomograph and a transmission scan obtained using a Ge-68 ring source for attenuation correction. An intra-arterial catheter was placed in the femoral artery opposite to the lower extremity using a venous catheter. One hour after carbidopa treatment, FDOPA, 4-FMT, or 6-FMT (�1 mCi/kg) was adminis tered i. v.
A dynamic scanning protocol consisting of regular scans (10 x 90 s and 3 x 300 s) over the first 30 min and 18 5-min interleaved scans over the next 90 min was per formed. Interleaved scanning was accomplished by shift ing the scanner bed position back and forth by 0.1687 cm (i.e., half the regular plane distance) between adjacent time frames. Images were reconstructed with a recon struction filter (Hann filter with cut off at the Nyquist frequency), which gives an in-plane resolution compara ble to the axial resolution (�5 mm full width at half max imum). Arterial blood samples were obtained at 12-s in tervals for 2 min after injection. Thereafter, samples were obtained every minute from 2-5 min and then at 7, 10, 30, 60, 90, and 120 min for determinations of time activity curves and plasma concentrations of peripheral metabo lites of the radiofluorinated amino acid. Emission scans were corrected for attenuation using the measured trans mission scan. During the study, pulse rate and blood ox ygenation were monitored with an oxymeter. Body tem perature was monitored and maintained constant with a heating blanket.
Determination of radiolabeled metabolites in plasma
Blood samples from tomographic studies were obtained and processed as previously reported (Melega et aI., 1991a) .
Central and peripheral metabolism in rodents
Male Sprague-Dawley rats (weighing 275-325 g) were anesthetized with halothane and provided with an intra jugular cannulae. Animals were allowed to recover and were housed individually for 1-2 days. On the day of the experiment (injection time between 9: 30 and 11 :00 a.m.), animals were pretreated with carbidopa (5 mg/kg s.c.) 60 min before injection of the radiolabeled amino acid (1.4 mCilkg Lv.) via the cannulae, in a volume of 0.4-0.8 mI. For experiments in absence of carbidopa, a similar pro tocol was used. Blood samples were withdrawn for pe ripheral metabolite analysis and were centrifuged (5,000
x g, 5 min) in an Eppendorf microfuge at 4°C, and the plasma removed. To the plasma was added an equal vol ume of a cold solution containing 0.8 M perchloric acid, 1.0% Na2S20S' and 0.1 % EDTA; the resulting suspension was centrifuged and then filtered (0.2 jLm) before HPLC analysis. After blood samples were taken, animals were immediately killed by decapitation. Striata and cerebel lum were dissected rapidly (within 3 min) on an ice chilled aluminum plate, blotted, immersed in liquid nitro gen, weighed, and counted for total 18F activity. Tissues were homogenized in 0.5 ml of a solution containing 0.4 M perchloric acid, 0.5% Na2S20S' and 0.05% EDTA, cen trifuged, and filtered (0.2 jLm) before HPLC analysis. Ex traction of 18F radioactivity from plasma was essentially quantitative (>95%); from striatum and cerebellum, it was >85% (Melega et aI., 1990b) . Values reported are uncorrected for extraction efficiency and corrected for 18F decay.
Analytical methods
The HPLC system consists of a Beckman 210 solvent delivery system with the following mobile phase for plasma analysis: 80% 0.1 M NaH2P04, 1.7 mM (2.3 mM for brain samples) octane sulfonic acid sodium salt, 0.1 mM EDTA, pH 3.1 (pH 3.3 for brain samples), and 20% MeOH at a flow rate of 1.0 ml/min. A guard cell ( + 0.45) (ESA, Chelmsford, MA, U.S.A.) preceded a Rheodyne 7125 injector (Cotati, CA, U.S.A.) fitted with a 100 jLl loop. A guard column (30 x 4.6 mm, 5 jLm; Brownlee, Foster City, CA, U.S.A.) was used in conjunction with a C I 8 reverse phase column (250 x 4.6 mm, 5 jLm; Beck man, Fullerton, CA, U.S.A.). The analytical cell (model 5011, ESA) was set at an applied potential of + 0.02 V (detector 1) and + 0.4 V (detector 2) and coupled to a coulochem controller (model 5100A, ESA) to monitor en dogenous catecholamine and carbidopa levels. Fractions (1 mllmin) were collected and counted for radioactivity (decay corrected) in an NaI well counter. For FDOPA, radioactivity peaks were identified by comparison of their retention times with those of authentic metabolite stan dards (Lux en et aI., 1987) .
Data analysis
Separate regions of interest (ROIs) (�0.9 cm 2 on a cross-sectional plane of largest striatal area) for the left and right striata were defined according to the apparent boundary of the structure on the PET image (summed from 30 to 120 min). ROIs (�2.0 cm 2 ) for the cerebellum were similarly defined, but were based on summed PET images 1-10 min postradiotracer injection. These ROIs were then applied to the serial PET images at various scan times to give striatal and cerebellar time activities. Curves from the left and right sides were averaged to give one striatal and one cerebellar curve for each study.
Arterial plasma time-activity curves (T AC) of radiola be led amino acids (6-FMT, 4-FMT, FDOPA) were ob tained from the total plasma radioactivity time-activity curves and measured fractions of the original compound, according to the modeling approach previously described (Huang et aI., 1991) . Tissue T AC and plasma TAC, de termined above, were then used to examine the transport and uptake characteristics of the radiolabeled probe in tissue. The three-compartmental model previously devel oped for FDOPA kinetics (Huang et aI., 1991) was used, with KI representing the forward BBB transport constant of the original labeled tracer; k2, the reversed BBB trans port rate constant; k3, the decarboxylation rate constant; and k4' the clearance ' rate constant of decarboxylated spe cies (and/or their metabolites) from tissue to plasma. For FDOP A, the peripheral metabolite 3-0MFD crosses the BBB and a single reversible compartment was included to describe the kinetics of 3-0MFD (Huang et aI., 1991) . For 6-FMT and 4-FMT, no peripheral 3-0-methylation oc curs; therefore, no plasma labeled metabolites were as sumed to cross the BBB in a significant manner. The model fitting procedure was performed using BLD (Car son et aI., 1981), a software package for kinetic data mod eling and simulation. The uptake constant (K3) of the la beled tracer from plasma to tissue was calculated from the estimated values of KI, k2, and k3 as Klk3/(k2 + k3). The value of K3 was also estimated by Patlak analysis (Patlak et aI., 1983) using tissue TACs from 30 to 60 min and the entire plasma TAC of the labeled tracer (exclud ing all labeled metabolites). Analysis of variance (ANOV A) was used to determine whether the results among these three tracers were different. A p-value of < �.05 was considered statistically significant in the anal
YSIS.
Tomographic three-dimensional (3D) imaging process
Stereo paired 3D images of brain FDOP A PET images were prepared using the A VS5.1 software system (A VS Inc., Waltham, MA, U.S.A.) on a Sun SPARC 10/41 workstation. Brain FDOPA PET images were first seg mented by thresholding the image pixel values into three levels, resulting in images consisting of only three differ ent regions, namely, (a) one of high specific tracer up take, (b) one of low tracer uptake, and (c) one outside of the animal's head. An edge detection technique was used to determine the surfaces of the cranium and the struc tures of high specific tracer uptake. Lighting and shading from the surfaces were generated by ray tracing (486 x 486 with interpolation). Moderate transparency was ap plied to the cranial surface (in blue), while the surfaces of specific uptake structures were opaque (yellow). Stereo pairs were produced by 3D lateral movement of the object in generating the lighting and shading (i.e., the ray tracing step).
RESULTS
Brain and peripheral kinetics (monkeys) Figure 1 shows typical images 90-120 min after systemic injection of the radiolabeled amino acids (6-FMT, 4-FMT, and FDOPA) in nonhuman pri mates [CO aethiops (vervet), n = 9]. Accumulation of radioactivity was consistent with localization of central dopamine-rich structures (Hefti et al., 1981) . In all cases, specific (striatum) to nonspecific (cer ebellum) ratios increased with time ( Table 1) . How ever, these ratios are dependent on the radiolabeled amino acid being higher for 6-FMT (and 4-FMT) than for FDOPA. These new radiofluorinated m-ty rosine analogs also accumulated in innervation sites rich in aromatic amino acid decarboxylase (e .g., brain stem), as shown in Fig. 2 with 6-FMT. Figure  3 shows representative arterial plasma total radio activity and 6-FDOPA (t1 /2 = 23 min), 4-FMT (t1 /2 = 32 min), and 6-FMT (t1 /2 = 57 min) clearance curves in monkeys. Table 2 shows the metabolite compo sition at selected time points (90 and 120 min postin jection) obtained from the monkey arterial plasma activity curves. The plasma FDOPA metabolite profile comprised mainly FDOPA and 3-0MFD, consistent with previous observations in monkeys (Melega et aI., 1990a (Melega et aI., , 1991a . Other metabolites (e.g., FDA sulfoconjugate, 7.1 ± 2.3%) derived from incomplete inhibition of peripheral AAAD with carbidopa were also observed. Both radioflu orinated L-m-tyrosines, 4-FMT and 6-FMT, showed different arterial plasma metabolite profiles. As ex-FIG. 2. Three-dimensional stereopaired PET images (posterior view) of a monkey brain, integrated from 90 to 120 min after injection of 6-FMT. Note distribution of activity (yellow) in the basal ganglia and brain stem. Cranial outline is shown in blue; a portion of cranial outline has been erased for clarity. (Roth, 1986) . Similarly, 4-FMA, formed by AAAD mediated decarboxylation of 4-FMT, is also subse quently conjugated by phenolsulfotransferase in pe ripheral tissues. In contrast to 6-FMA, however, 4-FMA suffers extensive MAO oxidation to form 4-fluoro-3-hydroxyphenylacetic acid (FPAC) as its final metabolite, as estimated by HPLC. Similar re sults were also observed peripherally in rodents ( Fig. 4) . Figure 5 shows tissue T ACs in striatum and cer ebellum of monkeys for the three radiolabeled amino acids and their model-fitted curves. For the same injected dose (1 mCi/kg), striatal uptakes were in the order of 6-FMT > 4-FMT > FDOPA. The continuing rise of striatal radioactivity 30 min after 6-FMT injection was consistent with the relatively high 6-FMT time-dependent plasma concentration (Fig. 3) . The slower plasma clearance for 6-FMT compared with those of 4-FMT and FDOPA was also reflected in the cerebellar activity. In the case of FDOPA, the relatively high cerebellar level at late times was mostly due to the presence of 3-0MFD (Melega et a., 1990b) , which crossed the BBB from the plasma. It should be noted that the apparent decrease of the striatal 4-FMT accumula tion after 30 min (Fig. 5 ) was related to the fast decrease in cerebral 4-FMT concentrations that fol lowed its rapid rate of plasma clearance and was not due to a larger clearance rate of labeled metabolites produced in brain tissue (see model-fitting results below). For FDOPA, the striatal activity and plasma FDOPA concentrations also fell rapidly; this was offset by an increase in plasma 3-0MFD, which was transported from plasma across the BBB. Therefore, the fall of the striatal FDOPA curve was not as apparent as that of 4-FMT.
Model fitting of the striatal TAC of 6-FMT and 4-FMT showed that the three-compartmental model developed originally for FDOPA (without the com ponent for the peripheral metabolite 3-0MFD) can adequately describe the striatal kinetics of these tracers (solid curves in Fig. 5) . Estimated values of the model parameters for 6-FMT and 4-FMT are summarized in Table 3 along with those for FDOPA. The k4 value for FDOPA was fixed to zero in the model fitting. Allowing it to be variable gave slow convergence and large correlation among dif ferent estimated parameters (a sign of over-para meterization). This was not the case for 6-FMT and 4-FMT. Only the values of distribution volume and K3 were found to be significantly different (at p < 0.05 level) among the three tracers. The uptake con stants (K3) of both 6-FMT and 4-FMT were each larger than the corresponding value for FDOPA, but only the decarboxylation rate constant (k3) of 6-FMT was significantly larger than that of 
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Amine Amine Sulfates FDOPA. The uptake constants, as calculated from the model fitting results, were found to be compa rable to the values separately estimated by Patlak analysis, which assumes unidirectional uptake of tracer in tissue (Patlak et aI., 1983) . This consis tency further indicates that the clearance rates (k4) of the three tracers from the striatum were rela tively small during the first 2 h after their injection. Comparable values of KJ and k2 among the three tracers indicated that their BBB transport rates were not significantly different. The cerebellar tissue kinetics can also be fitted well by the same compartmental model, except that the clearance rate constant (k4) was relatively small and could not be determined reliably with the avail able data. The values summarized in Table 3 were obtained by setting the k4 value to zero. None of the estimated values were statistically different among the three tracers except for K3. The K3 value of 6-FMT in cerebellum is nonzero and was signifi cantly larger than that of FDOPA. However, the modeling analysis of the present data could not de- Arterial plasma metabolite profile in rats (carbidopa, 5 mg/kg), 30 min after injection of 6-FMT (shaded), 4-FMT (white), or FDOPA (black). Note the absence of COMT products with the radiofluorinated L-m-tyrosine analogs (*) ; 3-0MFD is the most prominent metabolite in arterial plasma at the same time point. However, an increase in AAAD products and, conse quently, MAO oxidation products, is observed with the radiofluorinated L-m-tyrosine deriva tives (see text for discussion). 4-FMT: mean ± 1SD; FDOPA and 6-FMT: mean of two determi nations. Conversion rate constants in plasma (Huang et aI., 1991) are as follows: 6-FMT: 0.0082 ± 0.0070 min -1; 4-FMT: 0.0195 ± 0.0019; and FDOPA: 0.0115 ± 0.0013.
termine whether this was due to decarboxylation of the 6-FMT in cerebellum or due to a nonzero BBB permeability of plasma 6-FMA.
Tissue and peripheral metabolism (rodents)
A comparative distribution of radioactivity pro files in rodent brain striatum 30 min after radiola beled amino acid administration is shown in Fig. 6 . For FDOPA, FDA (33 ± 4%) and 3-0MFD (51 ± 4%) were the predominant metabolites; small amounts of FDOPA (1 ± 0.3%) and FDA metabo lites (FHVA, FDOPAC and conjugates, 4 ± 0.5%) were also observed. Consistent with the observa tions in peripheral tissues in both monkeys (Table 2) and rodents (Fig. 4) , 6-FMT (28 ± 5%) and 6-FMA (53 ± 6%) and its amine conjugate (4 ± 3%) were observed in rodent striatum. Similarly, 4-FMT re sults in the same tissue paralleled those observed peripherally in rodents ( Fig. 4 ) and monkeys (Table  3) . Interestingly, the product of 4-FMA oxidation was the most significant radiolabeled product ob served in striatal tissue (Melega et aI., 1989) . Dis- tribution of total activity profiles was also deter mined in rodent striatum, cerebellum, and arterial plasma 30 min after i. v. administration of 6-FMT in the presence of carbidopa (Fig. 7) . The presence of 6-FMA in cerebellar tissue is consistent with low, but significant, levels of AAAD in rat cerebellum (Rahman et al., 19810) . The paralleled FMT metab olite(s) profiles between cerebellum (Fig. 7B) and plasma (Fig. 7C) , however, may not discount 6-FMA BBB permeability. Accordingly, in absence of carbidopa, when significant peripheral decarbox ylation of 6-FMT exists, an increase in 6-FMA in cerebellum was observed (Fig. 8C ) when compared with the same experiment in the presence of carbi dopa (Fig. 8B) . Similarly, total 6-FMA activity in striatum was decreased (Fig. 8A ).
DISCUSSION
Brain kinetics: kinetic rate constants in striatum (monkeys) It has been shown that FDOPA presents excel lent specificity for AAAD, and, indeed, probes cen tral dopaminergic mechanisms in vivo (Barrio, 1991) . Specific accumulation of 18 F activity in the basal ganglia is attributed to the AAAD-mediated formation of FDA and its metabolites (Cumming et al., 1987; Melega et al., 1990b) . However, interpre tation of FDOPA kinetic data is far from clear, and important issues still remain unanswered about the in vivo use of FDOPA with PET. Beyond the bio chemical uncertainties associated with FDOPA de terminations, among others, the quantitative rela tionship between FDOPA kinetics and endogenous dopamine synthesis (Barrio, 1991) , the high nonspe cific tissue background, and the use of ROIs still present problems for quantitative interpretation of the data (Yu et al., 1993) . The issue of FDOPA sensitivity is particularly critical with dopaminergic cell degeneration in idiopathic Parkinson's disease or MPTP exposure (Barrio et al., 1990) .
The introduction of fluorinated L-m-tyrosine an alogs is designed to develop new in vivo approaches and new tools to characterize biochemical pro cesses occurring at neuronal terminals. The use of fluorinated m-tyrosine analogs is supported by a strong biochemical and pharmacological rationale. For example, we find that (a) m-tyrosine is an ex cellent substrate for AAAD (Awapara et al., 1962; Srinivasan and Awapara, 1978; Borri-Voltattorni et al., 1983) ; the Km and Vmax values derived from Lineweaver-Burk plots indicate that L-m-tyrosine behaves as a better substrate than does L-DOPA (Borri-Voltattorni et al., 1983) ; (b) BBB transport of 4-FMT is significant (Melega et al., 1989) ; (c) newly obtained in vitro data (Barrio et al., 1995) on the neuronal vesicular transport of radiofluorinated m-tyramines indicate that, similar to dopamine, ra diofluorinated m-tyramines are substrates for the energy-dependent vesicular transporter and, there fore, stored in vesicles after its AAAD-mediated formation; (d) in in vitro evaluation of affinity at dopamine D-1 and D-2 receptor subtypes, 4-FMA had a similar affinity ( �twofold less affinity) for D-1 and D-2 binding sites than dopamine (Claudi et al., 1992) . Other fluorinated phenylethylamines also show significant affinities for postsynaptic recep tors, implicating that the catechol moiety is not re quired (Cardellini et al., 1988) ; (e) structural re quirement analysis of substrates for the striatal do pamine reuptake carrier has shown that the 3-hydroxy group of dopamine is critical for trans port (Meiergerd and Schenk, 1994) ; indeed, m-tyra mine inhibited the transport of dopamine as effec tively as a catechol-containing derivative (Km = 2.6 ± 0. 4 jJ.. M versus 1.1 ± 0.1 jJ.. M for dopamine); and FIG. 6. Striatal brain tissue metabolite profile in rats (carbidopa 5 mg/kg), 30 min after i.v. admin istration of 6-FMT (shaded), 4-FMT (white), or FDOPA (black). After administration of FDOPA, 3-0MFD was the most abundant metabolite found in rat striatum, contributing significantly to tissue-background activity. FDOPA metabo lites (MAO oxidation products)t are a combina tion of FDOPAC and FHVA. No COMT products are observed for 6-FMT or 4-FMT. 6-FMA, result ing from the AAAD-dependent decarboxylation, was the major metabolite found from 6-FMT. Products of MAO oxidation, after AAAD dependent decarboxylation, were prevalently found from 4-FMT (see text for discussion). 6-FMT and 4-FMT: mean ± 1SD (n = 3); and FDOPA, mean of two determinations.
[L (D both 4-FMA and 6-FMA are substrates for MAO A oxidation (Barrio et aI., 1995) . The data presented herein confer validity to the assertion that, like FDOPA, both 4-FMT and 6-FMT have, a priori, all the given conditions to be appropriate in vivo probes for dopaminergic mech anisms. Further support comes from evidence sug gesting that phenylethylamine and dopamine and their metabolites are co-localized in the nigrostriatal system, more specifically, in tyrosine hydroxylase containing neurons (J uorio et aI., 1991) .
Indeed, this work demonstrates that both radio fluorinated m-tyrosine analogs of L-DOPA accumu-o o LL late selectively in striatal structures (Fig. 1) and have comparable or higher uptake constants than those of FDOPA (Table 3) ; in this regard, they com pare favorably with FDOPA because of their in creased signal-to-noise ratios (Table 1) . Striatal tis sue is better delineated with both 4-FMT and 6-FMT than with FDOPA, a particularly important feature when central dopaminergic structures had suffered degeneration (e .g., Parkinson's disease) or in determinations with small animals (e.g., squirrel monkeys) (data not shown). Moreover, 4-FMT and 6-FMT allow for a more sensitive detection of ad ditional innervations sites (e.g., brain stem), with high AAAD concentrations in all animal species in vestigated (Kuntzman et aI., 1961; McCaman et aI., 1965; McKay et aI., 1978; Rahman et aI., 1981b) (Fig. 2) . Lastly, a lower background level allows the use of properly validated methods (Muller-Gartner et aI., 1992) to correct for partial volume effects (Hoffman et aI., 1979) to give more accurate and reliable measurements.
The substantially increased sensitivity with the radiofluorinated L-m-tyrosines (Table 3 ) appears re lated to at least two factors. The first is that striatal uptake (normalized by amount injected and body weight) follows the order 6-FMT :? 4-FMT > FDOPA (p < 0.05). The increased uptake constant (K3) (Hoffman et aI., 1992) from plasma to tissue, with 6-FMT > FDOPA (p < 0.05) and 4-FMT > FDOPA (p < 0.05) is a reflection of increased rates of AAAD-mediated decarboxylations. The second is the lack of peripheral 3-0-methylation for 4-FMT and 6-FMT, which reduces the significant tissue background from this source (e.g., 3-0MFD) ( Table  3) . As a result of the two factors stated above, the A B striatal-to-cerebellum ratios follow the order 6-FMT = 4-FMT > FDOPA (with 6-FMT > FDOPA, and 4-FMT> FDOPA) (p < 0.05).
Brain biochemistry: striatal metabolites (rodents)
The three-compartmental model configuration (Huang et aI., 1991) describes the tissue and plasma kinetics for all radiofluorinated analogs as measured with PET in nonhuman primates. From the kinetic data, this modeling approach provides information on BBB transport, AAAD-mediated decarboxyl ation rates, as well as the rate of release of tissue metabolites. However, even though similar delinea tion of central brain structures and tissue kinetics can be described for FDOPA, 4-FMT and 6-FMT ( Fig. I and Table 3 ), the molecular species involved in tissue trapping differ. Biochemical analyses of rat striatal tissue revealed that after 6-FMT i.v. admin istration (Fig. 6) , the main metabolite found in stri atum at 30 min was the product of AAAD-mediated decarboxylation, namely 6-FMA (54 ± 4%). The remainder was unmodified 6-FMT (28 ± 5%) and 6-FMA (18 ± 4%) oxidation metabolites. This is similar to the metabolite composition found after FDOPA administration, except for the absence of the peripherally generated 3-0MFD, which is com petitively transported from plasma to the brain. It has been shown earlier that conversion of FDOPA (and L-DOPA) to FDA (and dopamine) and metabolites occurs in corpus striatum mainly in do paminergic neurons (Hefti et aI., 1991; Melega et aI., 1990b) . Also, since noncatechol-containing phe nylethylamines have distribution and metabolism similar to dopamine (Juorio et aI., 1991) , it can be inferred from these data that 6-FMT nigrostriatal metabolism occurs predominantly in dopaminergic neurons. In addition, 6-FMA, by analogy with FDA (and dopamine) is not extensively metabolized to further products of central oxidation of monoam ines, and, therefore, also appears to be mainly stored in a slow turnover rate functional pool (Bar rio et aI., 1990; Melega et al., 1990b) . This is to be expected from newly obtained in vitro data on the neuronal vesicular transport and MAO A oxidation rates of 6-FMA, 4-FMA, and FDA (Barrio et aI., 1995) .
By virtue of the cerebral distribution of radioac tivity accumulation, 4-FMT metabolism is also ex pected to occur in tyrosine hydroxylase-containing neurons. However, metabolite distribution differed from that encountered with FDOPA or 6-FMT. At 30 min after 4-FMT administration in rats, most of the striatal activity (66 ± 5%) was attributed to 4-FPAC, the formation of which is mediated by cen tral MAO oxidation of 4-FMA, the product of 4-FMT decarboxylation. The remaining activity was 4-FMT (9 ± 4%), 4-FMA (19 ± 3%), and its sulfoconjugate (5 ± 1%). The presence of the MAO oxidation product, 4-FPAC, as the predominant striatal metabolite (Melega et aI., 1989) , suggests that after 4-FMT central decarboxylation, 4-FMA MAO central oxidation competes favorably with its vesicular transport. It is also apparent from the ki netic data in nonhuman primates, that the central release of monoamine metabolites from the brain is slow (Melega et aI., 1989) , complicating interpreta tion of k4 (Huang et aI., 1991) . Ideally, k4 should represent the rate of release of metabolites formed in striatal tissue. Whereas k4 :Ie-0, metabolite release appears limited by diffusion out of brain tissue.
Cerebellar and peripheral metabolites (rodents)
Chemical analysis of the radioactivity accumu lated in striatal tissue with all radiofluorinated probes supports the premise that its time-dependent accumulation can be attributed to central dopami nergic biochemistry. We have also examined in ro- Vol. 16, No. 4, 1996 dents the origin of the nonspecific (cerebellum) ac tivity with 6-FMT. From these data ( Figs. 7 and 8 ) and the peripheral metabolism of 6-FDOPA, 4-FMT, and 6-FMT in monkeys (Table 2) and ro dents (Fig. 4) , several conclusions can be extracted. Under conditions (carbidopa, 5 mg/kg) that cause almost complete inhibition of peripheral AAAD in both nonhuman primates and rodents, as judged by L-DOPA and FDOPA arterial plasma metabolite compositions (Meleg a et aI., 1990a), both 4-FMT and 6-FMT produced peripherally measurable amounts of decarboxylation products (and metabo lites). This is consistent with the observation that 0and m-tyrosines are better substrates for AAAD than are the catechol counterparts (e.g., L-DOPA or FDOPA) (Borri-Voltattorni et aI., 1983) , and, there fore, even low amounts of active AAAD would pro duce some decarboxylation products. Also, mon key species have consistently showed high periph eral levels of AAAD (Rahman et aI., 1981b) , and complete inhibition of peripheral AAAD, even at plasma concentrations of carbidopa well above those known to cause complete inhibition in hu mans (Hoffman et aI., 1992) , is rarely achieved. However, caution should be exercised with the in terpretation of the conversion rate constants of 4-FMT and 6-FMT in plasma (Huang et aI., 1991) (Fig. 4 ), because these results may reflect partial decarboxylation as well as differences in whole body volumes of distribution and/or excretion ki netics of the radiolabeled probes.
The presence of the radiofluorinated m-tyramines in the circulation, however, raises the possibility of their transport across the BBB. Whereas catechol amines (e.g., dopamine) are known to be poorly transported from plasma to brain tissue (Hardebo and Owman, 1980) , little reliable information exists on BBB permeability of m-tyramines. Tyramines, organic cations at physiological pH, may penetrate organic barriers by diffusion (lseki et al., 1993) , analogous to the transport of ammonia. Low, but measurable, amounts of 6-FMA were found in cer ebellar tissue, where local metabolism of 6-FMT may seem improbable (Nakazato et aI., 1992) . It must be recognized, however, that AAAD immuno reactive cells have been observed in cerebellum of hamsters, rats, and mice (Baker et aI., 1991) , for which a priori cerebellar AAAD-mediated decar boxylation of highly sensitive substrates (e.g., 4-FMT and 6-FMT) cannot be discounted. In the absence of carbidopa, however, cerebellar 6-FMA concentrations are higher (Fig. 8C) , suggestive of the blood-borne origin of cerebellar 6-FMA.
Since the relative rates of transport across the BBB should be dependent on relative plasma amine concentrations, it is clear that if any such penetra tion of plasma metabolites is to occur in the brain, it will be much lower in humans than in rodents or nonhuman primates. Variations in interspecies ki netics in the peripheral metabolism of radiopharma ceuticals has been recognized earlier . These variations are related to body size, blood flow, and enzyme concentrations and distri butions (Boxenbaum, 1982) . In addition to all the physiological differences between species, AAAD activity in human serum is -1 pmollmin/ml, whereas it is 44.7 pmollmin/ml in monkey and 60.0 pmol/min/ml in rat (Rahman et ai., 1981b) . There fore, a more efficient carbidopa inhibition may be expected in humans, considerably decreasing (or even eliminating) any background tissue activity due to plasma-borne amines (e.g., 4-FMA or 6-FMA). Comparative results with FDOPA in hu mans, monkeys, and rodents support this hypothe sis (Melega et ai., 1990a) .
In part due to the complexities of its metabolism, which reduces its sensitivity, FDOPA has endured intense scrutiny. Earnest efforts have been long un derway to simplify quantitation of data and reduce undesirable peripheral metabolism (Guttman et ai., 1993) . Two radiofluorinated L-m-tyrosines investi gated in this work show significant promise. In par ticular, 6-FMT appears to follow the dopaminergic pathway with decarboxylation, amine vesicle trans port, and metabolism in a manner similar to that found for FDOPA, but without its drawbacks. The promising initial results shown recently in humans with 6-FMT (Nahmias et al., 1995) seem to support this notion. Clearly, preliminary work with these radiofluorinated m-tyrosines (Melega et al., 1989) and the data presented in this work indicate that additional work with MPTP-lesioned animals is warranted. Clinical work with Parkinson's disease patients should follow.
